MARKET

JANX

JANX

Janux Therapeutics, Inc.
NASDAQ
15.95
-0.05
-0.31%
Opening 13:08 08/14 EDT
OPEN
16.00
PREV CLOSE
16.00
HIGH
16.06
LOW
15.71
VOLUME
190.66K
TURNOVER
--
52 WEEK HIGH
35.34
52 WEEK LOW
12.12
MARKET CAP
975.13M
P/E (TTM)
-9.7031
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA)
TipRanks · 18h ago
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Janux Therapeutics Inc (JANX) and Entrada Therapeutics Inc (TRDA)
TipRanks · 4d ago
Weekly Report: what happened at JANX last week (0803-0807)?
Weekly Report · 4d ago
Analyst Maintains Buy on Janux Therapeutics, Keeps $60 Price Target Unchanged on Strong Balance Sheet and Clinical Differentiation
TipRanks · 6d ago
Janux Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 6d ago
Janux Therapeutics Price Target Cut to $55.00/Share From $58.00 by Guggenheim
Dow Jones · 6d ago
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55
Benzinga · 08/07 17:00
Analysts Are Bullish on Top Healthcare Stocks: Janux Therapeutics Inc (JANX), Cytokinetics (CYTK)
TipRanks · 08/07 15:40
More
About JANX
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others.

Webull offers Janux Therapeutics Inc stock information, including NASDAQ: JANX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JANX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JANX stock methods without spending real money on the virtual paper trading platform.